静脉注射黏菌素的肾毒性：一项前瞻性评估。
Nephrotoxicity of intravenous colistin: a prospective evaluation.
作者信息
Falagas Matthew E, Fragoulis Konstantinos N, Kasiakou Sofia K, Sermaidis George J, Michalopoulos Argyris
机构信息
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
出版信息
Int J Antimicrob Agents. 2005 Dec;26(6):504-7. doi: 10.1016/j.ijantimicag.2005.09.004. Epub 2005 Nov 8.
Twenty-one patients who received intravenous colistimethate sodium (CMS) for at least 7 days for the treatment of multidrug-resistant Gram-negative bacterial infections were included in a prospective cohort study at 'Henry Dunant' Hospital in Athens, Greece. The mean (+/- standard deviation) and median daily doses, cumulative doses and duration of treatment of intravenous CMS were, respectively, 5.5 (+/- 1.9) and 6 million IU, 90.2 (+/- 52.0) and 72 million IU, and 17.7 (+/- 11.7) and 15 days (range 7-54 days). Three patients (14.3%) developed nephrotoxicity during treatment with CMS. The cumulative dose of administered CMS was statistically correlated with the difference in values of serum creatinine between the end and start of CMS treatment (r = 0.6, P = 0.004 by Spearman's test).
在希腊雅典的“亨利·杜南”医院进行的一项前瞻性队列研究中，纳入了21例因治疗多重耐药革兰氏阴性菌感染而接受静脉注射多粘菌素甲磺酸钠（CMS）至少7天的患者。静脉注射CMS的平均（±标准差）和中位数日剂量、累积剂量及治疗持续时间分别为5.5（±1.9）和600万国际单位、90.2（±52.0）和7200万国际单位，以及17.7（±11.7）和15天（范围7 - 54天）。3例患者（14.3%）在CMS治疗期间出现肾毒性。给予的CMS累积剂量与CMS治疗结束时和开始时血清肌酐值的差异具有统计学相关性（Spearman检验，r = 0.6，P = 0.004）。
Zotero 插件